

# RenaissanceRe Holdings (RNR)

\$200.85 (As of 02/13/20)

Price Target (6-12 Months): \$211.00

Long Term: 6-12 Months	Zacks Recommendation: (Since: 10/14/19) Prior Recommendation: Outperfo	<b>Neutral</b>
Short Term: 1-3 Months	Zacks Rank: (1-5)	2-Buy
	Zacks Style Scores:	VGM:C
	Value: C Growth: B	Momentum: F

# **Summary**

RenaissanceRe's fourth-quarter 2019 operating earnings per share of 52 cents missed the Zacks Consensus Estimate by 44%. However, the bottom line improved by 2500% year over year on solid revenues. Its shares have outperformed its industry in a year's time. It has also been witnessing steady premium growth over the last few quarters driven by Casualty and Specialty plus Property segments. The company has been acquiring companies to strengthen its business. It deploys capital backed by operational excellence and solid cash flows. It has been undertaking divestitures to streamline its operations. However, being a property and casualty insurer, RenaissanceRe remains exposed to high severity loss associated with catastrophic events. An increasing debt level induced high interest expense level, which in turn, weighs on the margins.

# **Data Overview**

Last EPS Surprise

52 Week High-Low	\$202.68 - \$141.00
20 Day Average Volume (sh)	256,830
Market Cap	\$8.9 B
YTD Price Change	2.5%
Beta	0.31
Dividend / Div Yld	\$1.40 / 0.7%
Industry	Insurance - Property and Casualty
Zacks Industry Rank	Top 40% (101 out of 255)

Last Sales Surprise	NA
EPS F1 Est- 4 week change	-0.0%
Expected Report Date	05/05/2020
Earnings ESP	0.0%
P/E TTM	21.9
P/E F1	13.4
PEG F1	1.4
P/S TTM	2.1

# Price, Consensus & Surprise



# Sales and EPS Growth Rates (Y/Y %)



# Sales Estimates (millions of \$)

\*Quarterly figures may not add up to annual.

	QI	QZ	Q3	Q4	Annual
2021					4,312 E
2020					4,157 E
2019	635 A	1,028 A	1,022 A	1,083 A	3,767 A
EPS E	stimates				
	Q1	Q2	Q3	Q4	Annual*
2021	\$4.41 E	\$4.30 E	\$3.43 E	\$4.18 E	\$15.92 E
2020	\$3.91 E	\$4.14 E	\$3.13 E	\$3.90 E	\$14.96 E
2019	\$3.60 A	\$4.78 A	\$0.29 A	\$0.52 A	\$9.13 A

The data in the charts and tables, including the Zacks Consensus EPS and Sales estimates, is as of 02/13/2020. The reports text is as of 02/14/2020.

-44.1%


#### Overview

Founded in 1993 and based in Hamilton, Bermuda, RenaissanceRe Holdings Ltd. primarily provides property-catastrophe reinsurance to insurers and reinsurers globally on the basis of excess of loss (coverage of losses over a specified limit). Additionally, RenaissanceRe provides certain specialty reinsurance coverage on accident, health, aviation and satellite concerns, as well as homeowners' insurance in various parts of the U.S. The company also writes specialty and catastrophe reinsurance through two joint ventures, Top Layer Re and Reinsurance, and through certain specialty reinsurance and primary insurance lines.

RenaissanceRe conducts its business through three reportable segments: *Property*, *Specialty* and *Other*.

The Property segment (accounted for 50.6% of the total gross premium written in 2019): This includes its catastrophe class of business, principally consisted of excess of loss reinsurance and excess of loss retrocessional reinsurance to insure insurance and reinsurance companies against natural and man-made catastrophes, and its other property class of business.

**Specialty (49.4%):** The Company writes Specialty reinsurance and insurance covering primarily targeted classes of business. The Company offers its casualty and specialty reinsurance products principally on a proportional basis, and it also provides excess of loss coverage.





The company's **Other** segment category primarily includes the results of its share of investments in certain markets. It also includes the results of its investment unit, which manages and invests the funds generated by its consolidated operations.



### **Reasons To Buy:**

- ▲ Price Impact: Shares of RenaissanceRe have outperformed its industry in a year's time. Growing premiums, strategic portfolio realignment and an effective capital deployment should continue to drive the stock.
- ▲ Growing Premiums: RenaissanceRe has been witnessing a positive trend in gross premiums written, which has doubled over a span of five years, driven by premium growth at both its Casualty and Specialty plus Property segments. This upside is pretty visible from its five-year CAGR (2014 to 2019) of 25.4%, primarily led by strong segmental results. This consistent increase in premiums is likely to drive the top line further for RenaissanceRe.

Accelerated capital deployment and strategic divestitures should boost investor confidence. Its rising premiums on the back of solid segmental contributions also impresses.

- ▲ Inorganic growth: The company has been undertaking divestitures to streamline its operations by getting rid of low-return high-risk businesses. To this end it sold off its U.S based weather and weather-related energy risk management unit, to save itself from the uncertainties associated with that business. On the other hand, it is also acquiring and expanding businesses which provides scope to grow. In March2019, the company bought Tokio Millennium Re for a value of \$1.5 billion to increase the scale and boost the company's portfolio. We expect such strategic initiatives will enable the company to focus and grow its core operating business.
- ▲ Capital Position: The company has been witnessing growing free cash flow over the past few years. This is evident from its 2014-2019 CAGR of 26.5% for cash flow from operations. RenaissanceRe has been deploying excess capital in business over the past several quarters. It has been raising dividend since the past many years. In February 2019, the company again increased its payout by 3.1%. It currently has a dividend yield of 0.7%, higher than the industry average of 0.4%. We believe, the company's financial strength will continue to inspire investors' confidence.
- ▲ Profitability: Its return-on-equity (ROE) reflects growth potential. The company's trailing 12-month ROE of 8.5% compares favorably with the industry average of 6.9%, reflecting its efficiency in using its shareholders' funds.

#### **Reasons To Sell:**

▼ Catastrophe Loss: RenaissanceRe remains exposed to high severity loss associated with catastrophic events on a worldwide basis. In 2018, the company suffered a negative impact of \$340 million on underwriting results due to catastrophe losses. In 2019, the company faced a \$75-million of insured catastrophe losses, California wildfires, Typhoons Faxai and Hagibis in Japan and Hurricane Dorian in the Caribbean. Being a property and casualty insurer, the company is always exposed to cat activities, the occurrence of which imparts volatility to its results

Exposure to catastrophe loss as well as elevated debt level are some of the concerns facing the company.

- ▼ Increasing Debt Burden: The company's long-term debt has been rising due to funding of acquisitions, joint ventures and other investments. Debt has increased nearly fourfold in the last six years. In 2019, debt level increased 39.6% year over year. This ascending leverage also increases interest expenses, which more than doubled over the last five years. The trend also persisted during 2018 and 2019 with interest expenses climbing 6.5% and 24%, respectively, year over year. This deteriorating level of interest expenses continuously drains the margins.
- ▼ Overvalued: Looking at the company's valuation, investors might not want to pay any further premiums. The company's price to book ratio stands at 1.67, higher than its median of 1.5 and the industry's average of 1.4.

# **Last Earnings Report**

#### RenaissanceRe's Q4 Earnings Lag Estimates, Surge Y/Y

RenaissanceRe reported fourth-quarter 2019 operating earnings per share of 52 cents per share, missing the Zacks Consensus Estimate by 44%.

However, the bottom line improved significantly by 2500% year over year on the back of solid revenues.

12/2013	
Feb 04, 2020	
NA	
-44.09%	
0.52	
9.19	

12/2010

Quarter Ending

#### **Quarterly Operational Update**

RenaissanceRe's fourth-quarter operating revenues of \$1 billion soared nearly 101.7% year over year on the back of improved net premiums written plus net investment income.

Gross premiums written surged 65.3% year over year to \$905.4 million owing to higher premiums at the Property as well as the Casualty and Specialty segments.

Net investment income of \$113 million jumped 113.8% year over year.

RenaissanceRe's total expenses of \$1068 million escalated 57% year over year, primarily due to higher Net claims and claim expenses incurred, acquisition expenses, operational expenses, interest expenses and corporate expenses.

Underwriting loss of \$65.2 million was narrower than the year-earlier quarterly loss of \$82.3 million.

Combined ratio was 106.7% in the fourth quarter compared with the year-ago quarter's 114.3%.

#### **Quarterly Segment Update**

### **Property Segment**

Gross premiums written were \$245 million, up 22.6% year over year in the quarter.

Underwriting loss of \$87.1 million was reported in the quarter under review, wider than the year-ago loss of \$35 million. Combined ratio of 118.6% expanded 800 basis points (bps) year over year.

#### **Casualty and Specialty Segment**

Gross premiums written were \$660.5 million, up 89.9% from the prior-year quarter. This upside is driven by growth in the current and new business opportunities written in current and previous periods across several business classes, and business bought in connection with the TMR buyout.

The segment's underwriting income of \$20.8 million came in against the segment's underwriting loss of \$47.4 million.

Combined ratio of 95.9% contracted 2340 basis points year over year.

### **Financial Position**

As of Dec 31, 2019, total assets of RenaissanceRe were \$26.3 billion, up 41% from the level at 2018 end.

The company had total debt of \$1.4 billion as of Dec 31, 2019, up nearly 39.6% from the level at 2018 end.

Cash and cash equivalents were \$1379 million, up 24.5% from the figure at 2018 end.

Book value per share of \$120.53 rose 15.7% from the number at 2018 end.

Annualized return on equity for the quarter under review was 1.7%.

#### **Business Update**

In March 2019, the company closed the buyout of Tokio Millennium Re AG (now known as RenaissanceRe Europe AG), Tokio Millennium Re (UK) Limited (now known as RenaissanceRe (UK) Limited) and their subsidiaries.

#### **Recent News**

#### RenaissanceRe Declares Pricing of Secondary Public Offering of Common Shares — Jan 6, 2020

RenaissanceRe announced the pricing of an underwritten secondary public offering worth 1,739,071 shares by Tokio Marine & Nichido Fire Insurance Co., Ltd.

#### RenaissanceRe Announces Quarterly Dividend — Nov 13, 2019

RenaissanceRe recently announced that its board of directors approved a dividend of 34 cents per share. The amount will be paid out on Dec 31, 2019 to its shareholders of record on Dec13, 2019.

#### RenaissanceRe Declares Estimated Net Negative Impact From Q3 Catastrophe Events — Oct 15, 2019

RenaissanceRe estimates that the losses incurred due to third-quarter cat events will have an estimated net negative impact of \$155 million on the impending quarterly results. The losses stemmed from Typhoon Faxai and Hurricane Dorian.

#### **Valuation**

RenaissanceRe shares are up 41% over the trailing 12-month period. Over the past year, the Zacks sub-industry and sector are up 13.2% and 11%, respectively.

The S&P 500 index is up 22.2% in the past year.

The stock is currently trading at 1.67X trailing 12-month tangible book value, which compares to 1.45X for the Zacks sub-industry, 2.86X for the Zacks sector and 4.36X for the S&P 500 index.

Over the past five years, the stock has traded as high as 1.68X and as low as 1.03X, with a 5-year median of 1.24X. Our Neutral recommendation indicates that the stock will perform in-line with the market. Our \$211 price target reflects 1.75X tangible book value.

The table below shows summary valuation data for RNR

Valuation Multiples - RNR					
		Stock	Sub-Industry	Sector	S&P 500
	Current	1.67	1.45	2.86	4.36
P/B TTM	5-Year High	1.68	1.67	2.89	4.42
	5-Year Low	1.03	1.26	1.83	2.85
	5-Year Median	1.24	1.48	2.51	3.61
	Current	2.3	1.71	6.55	3.58
P/S F12M	5-Year High	3.83	11.26	6.65	3.58
	5-Year Low	2.1	1.56	5.39	2.55
	5-Year Median	2.88	1.89	6.04	3

As of 02/13/2020

# Industry Analysis Zacks Industry Rank: Top 40% (101 out of 255)

#### ■ Industry Price Industry ■ Price -200 380 -190 180 360 170 340 160 150 320 -140 -130 300 120 280 110 100 260 2020 90 2016 2017 2018 2019

# **Top Peers**

Neutral
Neutral
Neutrai

Industry Comparison Industry: Insurance - Property And Casualty			Industry Peers			
	RNR Neutral	X Industry	S&P 500	ARGO Neutral	SIGI Neutral	STC Neutra
VGM Score	С	-	-	В	С	А
Market Cap	8.87 B	1.79 B	24.56 B	2.20 B	4.17 B	959.38 N
# of Analysts	3	2	13	3	3	
Dividend Yield	0.68%	0.96%	1.78%	1.93%	1.32%	2.97%
Value Score	С	-	-	В	С	Α
Cash/Price	1.96	0.18	0.04	0.27	0.07	0.38
EV/EBITDA	-20.06	9.65	14.00	15.96	15.77	7.72
PEG Ratio	1.41	1.77	2.10	NA	9.77	N.A
Price/Book (P/B)	1.67	1.22	3.31	1.16	1.89	1.27
Price/Cash Flow (P/CF)	23.29	13.73	13.68	15.14	15.63	10.9
P/E (F1)	13.43	13.72	19.23	20.58	16.52	15.45
Price/Sales (P/S)	2.11	1.05	2.69	1.17	1.47	0.49
Earnings Yield	7.45%	7.03%	5.20%	4.86%	6.05%	6.47%
Debt/Equity	0.26	0.21	0.71	0.27	0.25	0.30
Cash Flow (\$/share)	8.62	3.05	6.92	4.24	4.47	3.7
Growth Score	В	-	-	D	С	Α
Hist. EPS Growth (3-5 yrs)	-3.39%	0.72%	10.85%	-5.09%	11.47%	6.08%
Proj. EPS Growth (F1/F0)	63.89%	12.38%	7.17%	123.69%	-3.79%	-4.73%
Curr. Cash Flow Growth	3.81%	12.19%	8.56%	651.83%	11.17%	7.12%
Hist. Cash Flow Growth (3-5 yrs)	-11.68%	7.23%	8.36%	2.81%	13.91%	7.63%
Current Ratio	1.59	0.44	1.23	0.54	0.30	3.3
Debt/Capital	42.73%	17.99%	42.91%	21.46%	20.06%	22.95%
Net Margin	17.82%	8.06%	11.81%	2.72%	9.55%	4.05%
Return on Equity	8.46%	7.50%	16.86%	3.30%	12.72%	9.55%
Sales/Assets	0.16	0.31	0.54	0.19	0.33	1.28
Proj. Sales Growth (F1/F0)	10.35%	4.10%	3.85%	7.57%	6.20%	0.00%
Momentum Score	F	-	-	A	В	С
Daily Price Chg	1.09%	0.20%	0.00%	-3.49%	1.58%	-0.69%
1 Week Price Chg	4.37%	1.84%	2.47%	2.59%	3.17%	-4.77%
4 Week Price Chg	4.05%	-0.15%	0.56%	-7.87%	2.85%	-1.00%
12 Week Price Chg	8.87%	4.12%	6.96%	3.79%	8.00%	-5.53%
52 Week Price Chg	40.89%	7.84%	16.68%	-4.71%	6.73%	-4.82%
20 Day Average Volume	256,830	85,417	2,020,569	132,073	227,543	141,13
(F1) EPS Est 1 week change	-1.94%	0.00%	0.00%	0.00%	0.00%	0.00%
(F1) EPS Est 4 week change	-0.01%	0.00%	-0.05%	0.00%	-0.16%	0.00%
(F1) EPS Est 12 week change	0.07%	0.00%	-0.17%	0.00%	0.79%	0.00%
(Q1) EPS Est Mthly Chg	-5.33%	0.00%	-0.24%	0.00%	3.51%	N/

# **Zacks Style Scores**

The Zacks Style Score is as a complementary indicator to the Zacks rating system, giving investors a way to focus on the highest rated stocks that best fit their own stock picking preferences.

Academic research has proven that stocks with the best Value, Growth and Momentum characteristics outperform the market. The Zacks Style Scores rate stocks on each of these individual styles and assigns a rating of A, B, C, D and F. We also produce the VGM Score (V for Value, G for Growth and M for Momentum), which combines the weighted average of the individual Style Scores into one score. This is perfectly suited for those who want their stocks to have the best scores across the board.

Value Score	С
Growth Score	В
Momentum Score	F
VGM Score	С

As an investor, you want to buy stocks with the highest probability of success. That means buying stocks with a Zacks Recommendation of Outperform, which also has a Style Score of an A or a B.

#### **Disclosures**

This report contains independent commentary to be used for informational purposes only. The analysts contributing to this report do not hold any shares of this stock. The analysts contributing to this report do not serve on the board of the company that issued this stock. The EPS and revenue forecasts are the Zacks Consensus estimates, unless indicated otherwise on the reports first page. Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts personal views as to the subject securities and issuers. ZIR certifies that no part of the analysts compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report.

Additional information on the securities mentioned in this report is available upon request. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Any opinions expressed herein are subject to change.

ZIR is not an investment advisor and the report should not be construed as advice designed to meet the particular investment needs of any investor. Prior to making any investment decision, you are advised to consult with your broker, investment advisor, or other appropriate tax or financial professional to determine the suitability of any investment. This report and others like it are published regularly and not in response to episodic market activity or events affecting the securities industry.

This report is not to be construed as an offer or the solicitation of an offer to buy or sell the securities herein mentioned. ZIR or its officers, employees or customers may have a position long or short in the securities mentioned and buy or sell the securities from time to time. ZIR is not a broker-dealer. ZIR may enter into arms-length agreements with broker-dealers to provide this research to their clients. Zacks and its staff are not involved in investment banking activities for the stock issuer covered in this report.

ZIR uses the following rating system for the securities it covers. **Outperform-** ZIR expects that the subject company will outperform the broader U.S. equities markets over the next six to twelve months. **Neutral-** ZIR expects that the company will perform in line with the broader U.S. equities markets over the next six to twelve months. **Underperform-** ZIR expects the company will underperform the broader U.S. equities markets over the next six to twelve months.

No part of this report can be reprinted, republished or transmitted electronically without the prior written authorization of ZIR.